Stock Track | Zai Lab Soars 5.52% Intraday on Earnings Beat and KarXT Commercial Launch Plans

Stock Track
Feb 27

Zai Lab's stock soared 5.52% during intraday trading on Friday, following the release of better-than-expected quarterly results and the announcement of upcoming commercial plans.

The pharmaceutical company reported a quarterly adjusted loss of 5 cents per share for the quarter ended December 31, beating analyst estimates of a 6 cent loss. Revenue also exceeded expectations, rising 17.1% year-over-year to $127.09 million compared to estimates of $124.47 million.

Investors responded positively to the earnings beat and the company's announcement of plans for the commercial launch of KarXT in the first half of 2026. Analyst sentiment remains bullish with a "buy" rating and a median 12-month price target of HK$22.46, representing approximately 35.5% upside from the previous closing price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10